Prof. Dr. YEŞİM ERALP

Metrikler

Yayın

104

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

1298

H-İndeks (WoS)

Atıf (Scopus)

1024

H-İndeks (Scopus)

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Eğitim Bilgileri

1998 - 2001

Tıpta Yandal Uzmanlık

İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye

1992 - 1998

Tıpta Uzmanlık

İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye

Akademik Unvanlar / Görevler

2004 - 2009

Doç. Dr.

İstanbul Üniversitesi, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı

2001 - 2005

Uzman

İstanbul Üniversitesi, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı

1992 - 1997

Uzman

İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü

1985 - 1991

Öğretim Görevlisi Dr.

İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü

Yönetimsel Görevler

2006 - 2010

Enstitü Müdür Yardımcısı

İstanbul Üniversitesi

Verdiği Dersler

Yüksek Lisans

OVER TÜMÖRLERİ

Lisans

TÜMÖR İMMÜNOLOJİSİ VE İMMÜNOTERAPİ

5. SINIF ONKOLOJİ UYGULAMA

HEDEFE YÖNELİK İMMUN ve GEN TEDAVİDE TEMEL İLKELER

ONKOLOJİDE HEDEFE YÖNELİK TEDAVİ

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

2024

1. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Mahidin E. I. B. M., Im S., Rihani J., Chung W., Babu K. G., Bowles J., et al.

Journal of Clinical Oncology , cilt.42, sa.23, ss.2812-2821, 2024 (SCI-Expanded)

2024

2. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Kilickap S., Ozturk A., Karadurmus N., Korkmaz T., Yumuk P. F., Cicin I., et al.

MEDICINE , cilt.103, sa.21, 2024 (SCI-Expanded)

2023

3. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Guner G., Aktas B. Y., Basal F. B., DEMİRKAZIK A., Gursoy P., Demirci U., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.149, sa.14, ss.13271-13277, 2023 (SCI-Expanded)

2023

4. Clinical Applications of Combined Immunotherapy Approaches in Gastrointestinal Cancer: A Case-Based Review

ERALP Y., Ates U.

Vaccines , cilt.11, sa.10, 2023 (SCI-Expanded)

2023

5. Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group

DOĞAN İ., AKSOY S., ÇAKAR B., BAŞARAN G., Ercelep O., Mandel N. M., et al.

CANCERS , sa.6, 2023 (SCI-Expanded)

2022

6. Lung Cancer in Turkey

KAYI CANGIR A., Yumuk P. F., SAK S., AKYÜREK S., ERALP Y., Yilmaz U., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.17, sa.10, ss.1158-1170, 2022 (SCI-Expanded)

2022

7. Application of mRNA Technology in Cancer Therapeutics

ERALP Y.

VACCINES , cilt.10, sa.8, 2022 (SCI-Expanded)

2022

8. Laterality and survival in mesothelioma: A SEER database analysis.

Parekh J., Yerlikaya A., Xie Y., Eralp Y., Adjepong Y.

JOURNAL OF CLINICAL ONCOLOGY , sa.16, 2022 (SCI-Expanded)

2022

9. International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials

Smeltzer M. P., Scagliotti G., Wakelee H. A., Mitsudomi T., Roy U. B., Clark R. C., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.17, sa.5, ss.651-660, 2022 (SCI-Expanded)

2022

10. Factors predicting a lower likelihood of residual nodal disease in clinically-node positive patients undergoing sentinel node surgery after neoadjuvant chemotherapy for breast cancer

Cabioglu N., KARANLIK H., Igci A., Muslumanoglu M., TÜKENMEZ M., EMİROĞLU S., et al.

CANCER RESEARCH , sa.4, 2022 (SCI-Expanded)

2021

11. Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center

AK N., Toker A., KARA M., ÖZKAN B., Ulker M., Kaba E., et al.

TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY , cilt.29, sa.4, ss.487-495, 2021 (SCI-Expanded)

2021

12. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study.

Ak N., Ozkan B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.26, sa.3, ss.819-829, 2021 (SCI-Expanded)

2021

13. TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

CABIOĞLU N., ÖNDER S., Oner G., Karatay H., TÜKENMEZ M., Muslumanoglu M., et al.

BMC CANCER , cilt.21, sa.1, 2021 (SCI-Expanded)

2021

14. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

Peled N., Gillis R., Kilickap S., Froesch P., Orlov S., Filippova E., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.16, sa.3, 2021 (SCI-Expanded)

2021

15. Tim3 expression on tumor infiltrating lymphocytes is associated with poor response to neoadjuvan chemotherapy in patients with locally advanced triple negative breast cancer

CABIOĞLU N., ÖNDER S., Oner G., Karatay H., TÜKENMEZ M., Muslumanoglu M., et al.

CANCER RESEARCH , sa.4, 2021 (SCI-Expanded)

2020

16. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al.

LUNG CANCER , cilt.148, ss.48-54, 2020 (SCI-Expanded)

2020

17. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., et al.

Balkan medical journal , cilt.37, sa.2, ss.104-107, 2020 (SCI-Expanded)

2019

18. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients

Papadopoulou E., Tsoulos N., Tsantikidi K., Metaxa-Mariatou V., Stamou P. E., Kladi-Skandali A., et al.

PLOS ONE , cilt.14, sa.12, 2019 (SCI-Expanded)

2019

19. Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Kilickap S., Demirci U., Bugdayci F., Tural D., KORKMAZ T., PAYDAŞ S., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.10, 2019 (SCI-Expanded)

2019

20. The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study

Eralp Y., AK N., Yilmazbayhan D., ÖZKAN B., FERHATOĞLU F., DEMİRKAZIK A., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.10, 2019 (SCI-Expanded)

2019

21. Outcomes of Thymoma and Determinants of Survival: 16 Years Experience of a Tertiary Cancer Center

AK N., Toker A., Bayraktar S., ÖZKAN B., ÜLKER M. G., Dagoglu N., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.10, 2019 (SCI-Expanded)

2018

22. Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey

Kilickap S., Ozturk A., Karadurmus N., Korkmaz T., Yumuk P., ÇİÇİN İ., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.10, 2018 (SCI-Expanded)

2018

23. Possible role of stress, coping strategies, and life style in the development of breast cancer

YILDIRIM N., ÖZKAN M., Ilgun A. S., Sarsenov D., Alco G., Aktepe F., et al.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE , cilt.53, sa.3, ss.207-220, 2018 (SCI-Expanded)

2018

24. Preoperative Lymphedema-Related Risk Factors in Early-Stage Breast Cancer

Iyigun Z. E., Duymaz T., Ilgun A. S., Alco G., Ordu C., Sarsenov D., et al.

LYMPHATIC RESEARCH AND BIOLOGY , cilt.16, sa.1, ss.28-35, 2018 (SCI-Expanded)

2016

25. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients

Ilgun S., Sarsenov D., Erdogan Z., Ordu C., Celebi F., Pilanci K. N., et al.

JOURNAL OF BUON , cilt.21, sa.6, ss.1425-1432, 2016 (SCI-Expanded)

2016

26. Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Sen F., Tambas M., Ozkaya K., Guveli M. E., Ciftci R., Ozkan B., et al.

MEDICINE , cilt.95, sa.30, 2016 (SCI-Expanded)

2015

27. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer Survival and Response to Treatment

AYDINER A., Sen F., Tambas M., Ciftci R., Eralp Y., Saip P., et al.

MEDICINE , cilt.94, sa.52, 2015 (SCI-Expanded)

2015

28. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer

ÖZMEN V., ÖZÇINAR B., Bozdogan A., Eralp Y., YAVUZ E., DİNÇER M. Z.

EJSO , cilt.41, sa.10, ss.1368-1372, 2015 (SCI-Expanded)

2015

29. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

Icli F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., SAİP P. M., et al.

BREAST CANCER , cilt.22, sa.5, ss.480-485, 2015 (SCI-Expanded)

2015

30. Is Administration of Trastuzumab an Independent Risk Factor for Developing Osteonecrosis of the Jaw Among Metastatic Breast Cancer Patients Under Zoledronic Acid Treatment?

Pilanci K. N., Alco G., Ordu C., Sarsenov D., Celebi F., Erdogan Z., et al.

MEDICINE , cilt.94, sa.18, 2015 (SCI-Expanded)

2014

31. Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy

GEZER U., Keskin S., Igci A., TÜKENMEZ M., Tiryakioglu D., Cetinkaya M., et al.

ONCOLOGY LETTERS , cilt.8, sa.2, ss.845-848, 2014 (SCI-Expanded)

2014

32. Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?

Karabulut S., Aksit E., Tas F., Ciftci R., Aydiner A., Yildiz İ., et al.

TUMOR BIOLOGY , cilt.35, sa.5, ss.4323-4329, 2014 (SCI-Expanded)

2013

33. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial

SAİP P. M., Eralp Y., AYDOĞMUŞ ŞEN F., Karaca H., ÖZKAN M., ÇETİN B. E., et al.

BREAST , cilt.22, sa.5, ss.628-633, 2013 (SCI-Expanded)

2013

34. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer

Yildiz İ., Tas F., Kilic L., Sen F., Saip P., Eralp Y., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.72, sa.2, ss.437-444, 2013 (SCI-Expanded)

2013

35. Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2 alpha Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer

Eralp Y., Keskin S., YÖRÜKER E. E., Akisik E., Igci A., Muslumanoglu M., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.36, sa.3, ss.215-223, 2013 (SCI-Expanded)

2012

36. Association of clinical and pathological variables with survival in thymoma

AYDINER A., Toker A., Sen F., Bicakci E., KAYTAN SAĞLAM E., Erus S., et al.

MEDICAL ONCOLOGY , cilt.29, sa.3, ss.2221-2228, 2012 (SCI-Expanded)

2012

37. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain

Altundag K., DİZDAR Ö., Ozsaran Z., Ozkok S., Saip P., Eralp Y., et al.

Onkologie , cilt.35, sa.5, ss.254-258, 2012 (SCI-Expanded)

2011

38. Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study

Aydiner A., Sen F., KAYTAN SAĞLAM E., Oral E. N., Eralp Y., TAŞ F., et al.

CLINICAL LUNG CANCER , cilt.12, sa.5, ss.286-292, 2011 (SCI-Expanded)

2011

39. Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients

Saip P., Sen F., Vural B., Ugurel E., Demirkan A., Derin D., et al.

JOURNAL OF BUON , cilt.16, sa.2, ss.241-246, 2011 (SCI-Expanded)

2011

40. Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy

Keskin S., Muslumanoglu M., Saip P., Karanlik H., Guveli M., Pehlivan E., et al.

ONCOLOGY , cilt.81, sa.1, ss.30-38, 2011 (SCI-Expanded)

2009

41. Yolk sac tumours of the ovary: Evaluation of clinicopathological features and prognostic factors

Cicin I., Saip P., Guney N., Eralp Y., Ayan I., KEBUDİ R., et al.

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY , cilt.146, sa.2, ss.210-214, 2009 (SCI-Expanded)

2009

42. Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis

Saip P., Cicin I., Eralp Y., Karagol H., Kucucuk S., Alas R. C., et al.

JOURNAL OF NEURO-ONCOLOGY , cilt.93, sa.2, ss.243-251, 2009 (SCI-Expanded)

2009

43. Malignant Ovarian Germ Cell Tumors A Single-Institution Experience

Cicin I., Eralp Y., Saip P., Ayan I., Kebudi R., Iyibozkurt C., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.32, sa.2, ss.191-196, 2009 (SCI-Expanded)

2009

44. Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer.

Karagol H., Saip P., Eralp Y., Topuz S., Berkman S., Ilhan R., et al.

Tumori , cilt.95, ss.207-11, 2009 (SCI-Expanded)

2009

45. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger

Eralp Y., Smith T. L., Altundag K., Kau S., Litton J., Valero V., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.135, sa.1, ss.141-148, 2009 (SCI-Expanded)

2008

46. Factors affecting the prognosis of breast cancer patients with brain metastases

Saip P., Cicin I., Eralp Y., Kucucuk S., Tuzlali S., Karagol H., et al.

BREAST , cilt.17, sa.5, ss.451-458, 2008 (SCI-Expanded)

2008

47. Ovarian carcinoma with simultaneous breast and rectum metastases

Derin D., Eralp Y., Guney N., ÖZLÜK M. Y., Topuz E.

Onkologie , cilt.31, sa.4, ss.200-202, 2008 (SCI-Expanded)

2008

48. Impact of adjuvant chemotherapy with respect to level of hormone receptor expression in patients with hormone responsive breast cancer: Implications for endocrine resistance

Eralp Y., Sakallioglu B., Kucucuk S., Tuzlali S., Saip P., Igci A., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.26, sa.15, 2008 (SCI-Expanded)

2008

49. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer

Eralp Y., Derin D., ÖZLÜK M. Y., Yavuz E., Guney N., SAİP P. M., et al.

Annals of Oncology , cilt.19, sa.4, ss.669-674, 2008 (SCI-Expanded)

2008

50. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer

GEZER U., Eralp Y., Akisik E. Z., YÖRÜKER E. E., Saip P., Topuz E., et al.

CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V , cilt.1137, ss.175-179, 2008 (SCI-Expanded)

2008

51. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer

Derin D., Eralp Y., Ozluk Y., Yavuz E., Guney N., Saip P., et al.

CANCER INVESTIGATION , cilt.26, sa.7, ss.671-679, 2008 (SCI-Expanded)

2008

52. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy

GEZER U., Eralp Y., YÖRÜKER E. E., Akisik E. Z., Saip P., Topuz E., et al.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE , cilt.46, sa.3, ss.311-317, 2008 (SCI-Expanded)

2008

53. Leptomeningeal dissemination of ovarian carcinoma through a ventriculopenitoneal shunt

Eralp Y., Saip P., Aydin Z., Berkman S., Topuz E.

GYNECOLOGIC ONCOLOGY , cilt.108, sa.1, ss.248-250, 2008 (SCI-Expanded)

2007

54. Multifocal breast cancer in women <= 35 years old

Litton J. K., Eralp Y., Gonzalez-Angulo A. M., Broglio K., Uyei A., Hortobagyi G. N., et al.

CANCER , cilt.110, sa.7, ss.1445-1450, 2007 (SCI-Expanded)

2007

55. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer

KARAGÖL H., Saip P., Uygun K., Caloglu M., Eralp Y., TAŞ F., et al.

Medical Oncology , cilt.24, sa.1, ss.39-43, 2007 (SCI-Expanded)

2005

56. Women age <= 35 years with primary breast carcinoma - Disease features at presentation

Gonzalez-Angulo A., Broglio K., Kau S., Eralp Y., Erlichman J., Valero V., et al.

CANCER , cilt.103, sa.12, ss.2466-2472, 2005 (SCI-Expanded)

2005

57. Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer

Oral E., Aydiner A., Eralp Y., Topuz E.

MEDICAL ONCOLOGY , cilt.22, sa.4, ss.367-374, 2005 (SCI-Expanded)

2004

58. Thymidine labeling index: Prognostic role in breast cancer

Bilir A., Eralp Y., CABIOĞLU N., Agizhali B., Camlica H., Aydiner A.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.27, sa.4, ss.400-406, 2004 (SCI-Expanded)

2004

59. Women aged 35 years or younger with primary breast carcinoma: Disease features at presentation

Gonzalez-Angulo A. M., Broglio K., Eralp Y., Kau S., Erlichman J., Valero V., et al.

ANNALS OF ONCOLOGY , cilt.15, ss.58, 2004 (SCI-Expanded)

2004

60. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model

Eralp Y., Wang X., Wang J., Maughan M., Polo J., Lachman L.

BREAST CANCER RESEARCH , cilt.6, sa.4, 2004 (SCI-Expanded)

2004

61. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer - Consolidative intraperitoneal cisplatin in ovarian cancer

Topuz E., Eralp Y., Saglam S., Saip P., Aydiner A., Berkman S., et al.

GYNECOLOGIC ONCOLOGY , cilt.92, sa.1, ss.147-151, 2004 (SCI-Expanded)

2003

62. Prognostic factors in localized soft-tissue sarcomas.

Kaytan E., Yaman F., Cosar R., Eralp Y., Saip P., Darendeliler E.

American journal of clinical oncology , cilt.26, ss.411-5, 2003 (SCI-Expanded)

2003

63. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).

Alici S., Saip P., Eralp Y., Aydiner A., Topuz E.

American journal of clinical oncology , cilt.26, sa.4, ss.358-62, 2003 (SCI-Expanded)

2003

64. Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix

Eralp Y., Saip P., Sakar B., Kucucuk S., Aydiner A., Dincer M., et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , cilt.13, sa.4, ss.497-504, 2003 (SCI-Expanded)

2003

65. Prognostic factors in localized aggressive non-Hodgkin's lymphoma

Alici S., Bavbek S. E., Kaytan E., Eralp Y., Onat H.

American Journal of Clinical Oncology: Cancer Clinical Trials , cilt.26, sa.1, ss.1-5, 2003 (SCI-Expanded)

2003

66. Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix.

Eralp Y., Saip P., Sakar B., Tas F., Aydiner A., Topuz E.

European journal of gynaecological oncology , cilt.24, sa.3-4, ss.323-6, 2003 (SCI-Expanded)

2003

67. Resectable thymoma: Treatment outcome and prognostic factors in the late adolescent and adult age group

Eralp Y., Aydiner A., Kizir A., Kaytan E., Oral E., Topuz E.

CANCER INVESTIGATION , cilt.21, sa.5, ss.737-743, 2003 (SCI-Expanded)

2002

68. Aggressive non-Hodgkin's lymphoma treated at the Institute of Oncology, Istanbul: Treatment, outcome, and prognostic factors

Alici S., Bavbek S. E., Kaytan E., Başaran M., Eralp Y., Onat H.

American Journal of Clinical Oncology: Cancer Clinical Trials , cilt.25, sa.5, ss.502-508, 2002 (SCI-Expanded)

2002

69. Anemia in oncology practice: Relation to diseases and their therapies

TAŞ F., Eralp Y., BAŞARAN M., ŞAKAR B., Alici S., Argon A., et al.

American Journal of Clinical Oncology: Cancer Clinical Trials , cilt.25, sa.4, ss.371-379, 2002 (SCI-Expanded)

2002

70. Prognostic factors and survival in late adolescent and adult patients with small round cell tumors

Eralp Y., Bavbek S., Başaran M., Kaytan E., Yaman F., Bilgiç B., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.25, sa.4, ss.418-424, 2002 (SCI-Expanded)

2002

71. Clinical characteristics of gestational trophoblastic disease at a single institute

Alici S., Eralp Y., Saip P., Argon A., BAŞARAN M., Topuz E., et al.

Tohoku Journal of Experimental Medicine , cilt.197, sa.2, ss.95-100, 2002 (SCI-Expanded)

2001

72. Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100) - A phase II study

Basaran M., Bavbek E., Sakar B., Eralp Y., Alici S., TAŞ F., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.24, sa.6, ss.570-575, 2001 (SCI-Expanded)

2001

73. Thymidine labeling index in epithelial ovarian cancer

Salihoglu Y., Bilir A., Aydiner A., Erkan M., Tuzlali S., Eralp Y.

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS , cilt.75, sa.2, ss.171-176, 2001 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

2022

1. The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors

Dişel U., Köse F., Bilici A., Özgüroğlu M., Sağlam S., Şeker M., et al.

Journal of Oncological Science , cilt.8, sa.2, ss.87-93, 2022 (Scopus)

2020

2. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak

Sezer A., ÇİÇİN İ., Cakmak G. K., Gurdal S. O., Basaran G., Oyan B., et al.

TURKISH JOURNAL OF SURGERY , cilt.36, sa.2, ss.147-163, 2020 (ESCI)

2018

3. Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes

Ordu C., Pilanci K. N., Alco G., Elbuken F., Koksal U. I., Ilgun S., et al.

EUROPEAN JOURNAL OF BREAST HEALTH , cilt.14, sa.3, ss.173-179, 2018 (Hakemli Dergi)

2018

4. Impact of Personality Traits, Anxiety, Depression and Hopelessness Levels on Quality of Life in the Patients with Breast Cancer

Izci F., Sarsanov D., Erdogan Z. I., Ilgun A. S., Celebi E., Alco G., et al.

EUROPEAN JOURNAL OF BREAST HEALTH , cilt.14, sa.2, ss.105-111, 2018 (Hakemli Dergi)

2017

5. Roles of Biopsychosocial Factors in the Development of Breast Cancer

ÖZKAN M., Yildirim N., Disci R., Ilgun A. S., Sarsenov D., Alco G., et al.

EUROPEAN JOURNAL OF BREAST HEALTH , cilt.13, sa.4, ss.206-212, 2017 (Hakemli Dergi)

2016

6. The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus.

Eralp Y.

Translational oncogenomics , cilt.8, ss.1-7, 2016 (Hakemli Dergi)

2016

7. The Relationship between Bone Mineral Density and Estrogen Receptor Positivity in Patients with Breast Cancer

Iyigun Z. E., Pilanci K. N., Cabuk F. K., Ilgun S., Ordu C., Duymaz T., et al.

JOURNAL OF BREAST HEALTH , sa.3, ss.119-122, 2016 (ESCI)

2016

8. The Prognostic Impact of Molecular Subtypes and Very Young Age on Breast Conserving Surgery in Early Stage Breast Cancer

Ordu C., McGuire K., Alco G., Pilanci K. N., Koksal U. I., Elbuken F., et al.

CUREUS , cilt.8, sa.6, 2016 (Hakemli Dergi)

2016

9. True Local Recurrences after Breast Conserving Surgery have Poor Prognosis in Patients with Early Breast Cancer

Sarsenov D., Ilgun S., Ordu C., Alco G., Bozdogan A., Elbuken F., et al.

CUREUS , cilt.8, sa.3, 2016 (Hakemli Dergi)

2014

10. The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience

Eralp Y., Kilic L., Alco G., BAŞARAN G., Dogan M., Dincol D., et al.

JOURNAL OF BREAST HEALTH , cilt.10, sa.4, ss.209-215, 2014 (ESCI)

2002

11. An atypical presentation of metastatic gestational choriocarcinoma with maxillary sinus and subcutaneous involvement; report of a case with literature review.

Alici S., Bavbek S. E., Eralp Y., Argon A., Basaran M., Aydiner A., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.7, sa.4, ss.373-6, 2002 (Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler

2024

1. Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases

Bayram E., Basaran G., Gokmen E., Mandel N. M., Oyan B., Uskent N., et al.

Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)

2022

2. Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group

Eralp Y., Dogan I., AKSOY S., Cakar B., Basaran G., Ercelep O., et al.

San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 6 - 10 Aralık 2022, (Özet Bildiri)

2022

3. Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)

Orer H. S., Nomak G., Oksuzoglu B., Senturk R., ERALP Y., Yumuk F., et al.

Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 Eylül 2022, (Özet Bildiri)

2020

4. Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.

Disel U., Kose F., Bilici A., ÖZGÜROĞLU M., Saglam S., Seker M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, (Özet Bildiri)

2020

5. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

Basaran G., Demirci U., Yildiz F., Cicin I., Aktas B. Y., Ozturk B., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri)

2019

6. Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey

Demirci U., GÖKMEN E., Eralp Y., Gunduz S., SEZGİN GÖKSU S., KORKMAZ T., et al.

42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 14 Aralık 2019, cilt.80, (Özet Bildiri)

2019

7. Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2-inoperable locally advanced breast cancer (ABC): RIGHT choice study

Lu Y., Malwinder S. S., Azim H., Eralp Y., Im S., Yap Y. S., et al.

European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapur, 22 - 24 Kasım 2019, (Özet Bildiri)

2019

8. Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?

Kilickap S., Basal F. B., DEMİRKAZIK A., Gursoy P., Demirci U., ERMAN M., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, ss.637, (Özet Bildiri)

2019

9. Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer: RIGHT choice study

El Saghir N., Malwinder S., Azim H., Eralp Y., Im S., Yap Y. S., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, ss.140-141, (Özet Bildiri)

2017

10. The prognostic impact of chemotherapy induced amenorrhea in women treated with early stage breast cancer

Ordu C., Pilanci K. N., Elbuken F., Alco G., Koksal U. I., Ilgun S., et al.

42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, (Özet Bildiri)

2016

11. Follow-up of chemotherapy induced changes in anti-Mullerian hormone, antral follicle number and ovary volume in premenopausal breast cancer patients

Elbuken F., Ordu C., Sarsenov D., Ilgun S., Pilanci K., Erdogan Z., et al.

41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27, (Özet Bildiri)

2016

12. Neoadjuvam kemoterapi öncesi biyopsi ile doğrulanmış aksiller metastazı olan hangi hasta grubunda tedavi sonrası aksiller diseksiyon göz ardı edilebilir?

Karanlık H., Özgür İ., Bademler S., Şen F., Eralp Y., Fayda M., et al.

20. Ulusal Cerrahi Kongresi, 2016, Antalya, Türkiye, 13 - 17 Nisan 2016, ss.1, (Tam Metin Bildiri)

2015

13. Metaplastic breast carcinoma versus triple nehative breast cancer survival and response to treatment

AYDINER A., ŞEN F., ÇİFTÇİ R., RÜMEYSA Ç., ERALP Y., SAİP P. M., et al.

MEDİCİNE, 01 Aralık 2015, (Özet Bildiri)

2015

14. Concominant Chemoradiotherapy with Etoposide Cisplatin versus Docetaxel Cisplatin in Locally Advanced Non Small Cell Lung Cancer

ERALP Y., ŞEN F., MAKBULE T., ÖZKAYA K., BERKER Ö., ORAL E. N., et al.

NSCLC, 09 Eylül 2015

2015

15. Does adjuvant chemotherapy induced amenorrhea effect survival in operated premenopausal breast cancer patients

ORDU Ç., ALÇO G., KN P., S, İ., D, S., F, Ç., et al.

European Cancer Congress, 01 Eylül 2015, cilt.322, (Özet Bildiri)

2015

16. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment

G, A., ORDU Ç., D, S., F, Ç., ERDOĞAN Z., AĞACAYAK F., et al.

EUR J SUR ONCOL, 01 Mayıs 2015, cilt.94, (Özet Bildiri)

2014

17. Aksiller metastazı bulunan hangi hastalarda neoadjuvan kemoterapi sonrasında aksiller diseksiyon yapılmayabilinir?

Karanlık H., Özgür İ., Fayda M., Yavuz E., Mudun A., Saip P. M., et al.

19. Ulusal Cerrahi Kongresi, Antalya, Türkiye, 16 - 20 Nisan 2014, ss.1-1751, (Tam Metin Bildiri)

2006

18. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer

Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., TAŞ F., et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.174, (Özet Bildiri)

2004

19. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER-2/neu in a murine mammary carcinoma model

Eralp Y., Wang X., Wang J., Maughan M., Polo J., Lachman L.

27th Annual Charles A Colman San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 8 - 11 Aralık 2004, cilt.88, (Özet Bildiri)

Etkinlik Organizasyonlarındaki Görevler

Ekim 2024

Breastanbul 2024

Bilimsel Kongre / Sempozyum Organizasyonu

Arıkan A. E., Uras C., Bese F. N., Eralp Y., Aribal M. E., Taşkın F., et al.

İstanbul, Türkiye

Ocak 2024

16. Meme Kanserinde Yeni Yaklaşımlar

Bilimsel Kongre / Sempozyum Organizasyonu

Molinas Mandel N., Oyan Uluç B., Arıbal M. E., Beşe N., Çelik L., Esen İçten G., et al.

İstanbul, Türkiye

Mayıs 2023

Meme Kanseri Atölye Çalışması

Bilimsel Kongre / Sempozyum Organizasyonu

Arıkan A. E., Eralp Y., Güler S. A., Kıvılcım T., Korkmaz T., Sönmez Ö., et al.

İstanbul, Türkiye

Aralık 2022

Meme Kanseri Atölye Çalışması

Bilimsel Kongre / Sempozyum Organizasyonu

Arıkan A. E., Korkmaz T., Eralp Y., Sönmez Ö., Yücel S., Güler S. A., et al.

İstanbul, Türkiye

Kongre ve Sempozyum Katılımı Faaliyetleri

17 Ekim 2024 - 20 Ekim 2024

Karadeniz Onkoloji Günleri

Panelist

Trabzon-Türkiye

10 Ekim 2024 - 12 Ekim 2024

Breastanbul

Davetli Konuşmacı

İstanbul-Türkiye

26 Eylül 2024 - 29 Eylül 2024

On Targeted Master Oncology

Oturum Başkanı

İstanbul-Türkiye

23 Eylül 2024 - 23 Eylül 2024

Bahrein Meeting 23 September

Davetli Konuşmacı

Badiyah-Bahreyn

21 Eylül 2024 - 22 Eylül 2024

8. Jinekolojik Onkoloji Sempozyumu

Davetli Konuşmacı

İstanbul-Türkiye

07 Eylül 2024 - 08 Eylül 2024

İç Hastalıkları Kongresi

Davetli Konuşmacı

İstanbul-Türkiye

27 Haziran 2024 - 29 Haziran 2024

Uludağ Meme Kanseri Sempozyumu

Davetli Konuşmacı

Bursa-Türkiye

24 Mayıs 2024 - 26 Mayıs 2024

2. Onkolojide Yenilikler Sempozyumu

Davetli Konuşmacı

Girne-Kıbrıs (Kktc)

10 Mayıs 2024 - 11 Mayıs 2024

On Targeted Master Oncology Moleküler Onkoloji

Oturum Başkanı

Ankara-Türkiye

24 Nisan 2024 - 28 Nisan 2024

11. Türk Tıbbi Onkoloji Kongresi

Davetli Konuşmacı

Girne-Kıbrıs (Kktc)

27 Mart 2024 - 30 Mart 2024

Hedef Kanser

Oturum Başkanı

Girne-Kıbrıs (Kktc)

07 Mart 2024 - 09 Mart 2024

7.Karadeniz Meme Kongresi

Davetli Konuşmacı

Samsun-Türkiye

28 Şubat 2024 - 28 Şubat 2024

Temel Bilimlerden Klinik Bİlimlere Araştırma Toplantıları

Davetli Konuşmacı

İstanbul-Türkiye

02 Şubat 2024 - 04 Şubat 2024

4. Meme Kanseri Sempozyumu

Davetli Konuşmacı

İstanbul-Türkiye

13 Ocak 2024 - 14 Ocak 2024